Amyris (AMRS) Shares Down 12.1%

Amyris Inc (NASDAQ:AMRS) shares were down 12.1% during mid-day trading on Monday . The stock traded as low as $4.87 and last traded at $5.01. Approximately 5,093,736 shares traded hands during mid-day trading, an increase of 33% from the average daily volume of 3,839,544 shares. The stock had previously closed at $5.70.

Several research analysts have issued reports on AMRS shares. BidaskClub lowered shares of Amyris from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Amyris in a research report on Monday, December 31st. B. Riley decreased their price target on shares of Amyris from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 14th. Finally, Zacks Investment Research lowered shares of Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, January 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Amyris currently has an average rating of “Buy” and a consensus price target of $8.83.

The stock has a market capitalization of $436.20 million, a price-to-earnings ratio of -1.64 and a beta of 0.29.



Amyris (NASDAQ:AMRS) last posted its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.96). The business had revenue of $14.90 million for the quarter, compared to analysts’ expectations of $46.72 million. During the same quarter last year, the firm posted ($0.81) EPS. The business’s quarterly revenue was down 38.4% on a year-over-year basis. As a group, research analysts forecast that Amyris Inc will post -1.34 earnings per share for the current fiscal year.

In other news, CFO Kathleen Valiasek acquired 23,000 shares of the stock in a transaction on Tuesday, November 27th. The shares were purchased at an average cost of $4.37 per share, for a total transaction of $100,510.00. Following the transaction, the chief financial officer now owns 251,630 shares in the company, valued at approximately $1,099,623.10. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Eduardo Alvarez acquired 11,834 shares of the stock in a transaction on Thursday, December 13th. The shares were purchased at an average price of $4.23 per share, for a total transaction of $50,057.82. Following the completion of the transaction, the chief operating officer now owns 333,876 shares in the company, valued at approximately $1,412,295.48. The disclosure for this purchase can be found here. Insiders own 21.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vivo Capital LLC boosted its stake in shares of Amyris by 97.2% during the 3rd quarter. Vivo Capital LLC now owns 5,575,118 shares of the biotechnology company’s stock valued at $44,266,000 after buying an additional 2,748,407 shares during the period. BlackRock Inc. boosted its stake in shares of Amyris by 3,109.9% during the 2nd quarter. BlackRock Inc. now owns 1,714,555 shares of the biotechnology company’s stock valued at $10,955,000 after buying an additional 1,661,141 shares during the period. Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of Amyris during the 3rd quarter valued at $7,828,000. AWM Investment Company Inc. acquired a new stake in shares of Amyris during the 3rd quarter valued at $5,876,000. Finally, Northpointe Capital LLC acquired a new stake in shares of Amyris during the 3rd quarter valued at $3,646,000. Hedge funds and other institutional investors own 31.14% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Amyris (AMRS) Shares Down 12.1%” was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://dakotafinancialnews.com/2019/02/12/amyris-amrs-shares-down-12-1.html.

Amyris Company Profile (NASDAQ:AMRS)

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Further Reading: What is the Coverage Ratio?

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply